Six of 15 adults with severe peanut allergy could tolerate more peanut protein after swallowing capsules of processed stool from healthy donors, and the effect held at four months, according to findings published in Science Translational Medicine.
The 40 percent response rate is the headline, but the arithmetic underneath it matters more than the fraction. This was an open-label trial with no control group, in 15 adults, testing an intervention that is not available to anyone outside a research setting and should not be attempted in any form at home.
For families managing peanut allergy, the practical relevance is indirect. Nothing changes about carrying epinephrine, reading labels, or avoiding peanuts. What changed is that researchers now have a plausible biological mechanism to pursue.
Precise Numbers Behind the 40 Percent
The trial enrolled 15 adults, all of whom reacted to 100 milligrams of peanut protein or less, roughly half a peanut, on a food challenge at baseline. That is a severe threshold. The registered eligibility range was 18 to 40 years.
Participants swallowed 36 encapsulated frozen fecal microbiota transplant capsules from non-allergic donors over about three hours. The trial ran in two parts. Among the 10 who received capsules alone, three showed an increased peanut reactivity threshold. Among five who were pretreated with antibiotics to clear their existing gut bacteria first, three responded.
That is six of 15, sustained at four months and, in a subset, out to 12 months. The higher rate in the antibiotic group involves five people, a number far too small to establish that pretreatment helps. No safety issues were reported.
Durability is what separates this from a transient shift. Many allergy interventions produce desensitization that fades once dosing stops, which is a central frustration of oral immunotherapy. A single course producing improved tolerance up to four months afterward is a different kind of signal, though in a group this size it could still reflect chance or natural variation in individual reactivity thresholds.
Bile Acid Pathway the Researchers Traced
The immunology is what elevates this above a curiosity. In participants who responded, the transplant increased tolerogenic regulatory T cells and decreased the T helper 2 cells associated with allergic responses, the immune shift you would want to see if tolerance were being restored.
Researchers went further and identified a candidate mechanism. Responders had higher bile salt levels, suggesting donor microbes promote immune-regulatory cells through bile acid metabolism.
The animal work is the most persuasive part, because it included a control the human trial lacked. Mice given transplants from human responders were protected from peanut allergy. Critically, mice given non-responder microbiomes were not protected. Bacteroides species emerged as key drivers of tolerance induction.
Rima Rachid of Boston Children's Hospital, who directs the Food Allergy Program and led the work with Talal Chatila, the hospital's director of translational immunology, described the trial as the first to demonstrate that a microbiome-based therapy may improve food allergy in people while revealing how gut bacteria, their metabolites and the immune system interact. She also said larger studies are now essential to confirm the findings and identify which patients are most likely to benefit.
Boundaries of an Open-Label Trial in 15 Adults
This limitation belongs here rather than buried at the end. Open-label means everyone knew what they were receiving. There was no placebo group, and food challenge outcomes can be influenced by expectation on both sides.
The sample is 15 people. A 40 percent response rate in 15 participants carries wide statistical uncertainty, and the split by treatment arm rests on groups of 10 and five.
The population was adults. Peanut allergy is overwhelmingly a childhood condition, and nothing here establishes that the approach works or is safe in children, whose microbiomes and immune systems differ substantially.
Fecal microbiota transplantation also carries real risk. Donor screening exists because transmissible infections have occurred through FMT, including serious ones. This is a regulated investigational product delivered under medical supervision, not something that can be replicated with probiotics or any home method.
Realistic Outlook for Families Living with Peanut Allergy
The treatment landscape gives this research more weight than it would otherwise carry. Peanut oral immunotherapy was the only FDA-approved disease-modifying option, and the manufacturer discontinued that product, leaving no approved peanut immunotherapy on the market. Off-label desensitization protocols still require months of daily dosing and carry high rates of allergic reactions, taste aversion and nonadherence.
That vacuum is why an alternative mechanism attracts attention. It does not shorten the timeline. Larger, controlled trials are required before anyone can say this works.
Follow-up work is already underway. A registered phase 2 trial with the University of Minnesota is evaluating an oral encapsulated microbiota preparation in peanut-allergic patients, and Rachid has said further work will test a purified, concentrated formulation in adolescents and in combination with peanut oral immunotherapy.
Families interested in participating can search ClinicalTrials.gov and discuss eligibility with an allergist. In the meantime, the standard of care is unchanged: strict avoidance, current epinephrine auto-injectors that have not expired, an anaphylaxis action plan shared with schools and caregivers, and prompt use of epinephrine followed by emergency care for any suspected anaphylactic reaction.
Nobody should attempt to increase their own tolerance by eating peanut, and nobody should purchase probiotic or microbiome products marketed as allergy treatments on the basis of this research.
The bottom line: the confirmed finding is that six of 15 adults tolerated more peanut after a single course of donor stool capsules, with effects lasting months and a plausible bile acid mechanism supported by mouse experiments, but this is early-stage research in a tiny uncontrolled group and nothing about allergy management changes today.
Frequently Asked Questions
What did the trial find? Six of 15 adults with severe peanut allergy showed an increased peanut reactivity threshold after taking 36 encapsulated fecal microbiota transplant capsules from non-allergic donors, with effects sustained at four months.
How were the responders split? Three of 10 who received capsules alone and three of five who were pretreated with antibiotics first. Those subgroups are far too small to conclude that antibiotic pretreatment helps.
What is the proposed mechanism? Responders showed more tolerogenic regulatory T cells, fewer allergy-associated T helper 2 cells, and higher bile salt levels, pointing to bile acid metabolism as the pathway.
How strong is the mouse evidence? Mice receiving responder microbiomes were protected from allergic reactions, while mice receiving non-responder microbiomes were not, which supports a microbiome-related effect.
Is this available as a treatment? No. It is a phase 1 investigational study. Larger controlled trials are needed before any approval.
Does it apply to children? The trial enrolled adults. Nothing here establishes safety or effectiveness in children.
What should families do now? Continue strict avoidance, keep unexpired epinephrine auto-injectors available, maintain an anaphylaxis action plan, and use epinephrine followed by emergency care for suspected anaphylaxis.
Article 5
Trying to Lower Blood Sugar, Cholesterol or Blood Pressure? Different Workouts Suited Different Markers
By: Elena Vega
Meta Description: A pooled analysis of 53 trials found different exercise types helped different metabolic markers. Most of the evidence was low certainty.
URL Slug: best-exercise-type-metabolic-syndrome-blood-sugar-cholesterol-blood-pressure
SEO Keywords: metabolic syndrome exercise, blood sugar workout, HIIT triglycerides, combined training, blood pressure exercise, waist circumference
No single form of exercise came out ahead across every marker of metabolic syndrome in a new pooled analysis, but different types did appear to suit different problems.
The network meta-analysis of ten exercise interventions, published in iScience, drew on 53 randomized controlled trials involving 2,948 participants with metabolic syndrome, with mean ages across trials ranging from roughly 36 to 73. Rather than asking whether exercise helps, which is already established, it asked which kind appeared to help most for which marker.
Metabolic syndrome is not one disease. It is a cluster diagnosed when someone has at least three of five conditions: high blood pressure, high blood sugar, excess abdominal fat, high triglycerides and low HDL cholesterol. That structure is why a single ranking was never likely.
Different Markers Responded to Different Training
Combined aerobic and resistance training ranked highest for improving body mass index, waist circumference, LDL cholesterol and fasting blood glucose. For someone whose main concerns are blood sugar and waistline, that combination performed best in this analysis.
High-volume high-intensity interval training was most effective for reducing body fat percentage.
Low-volume HIIT showed the greatest benefits for total cholesterol, triglycerides and diastolic blood pressure. The reported effects were a reduction of 0.36 mmol/L in total cholesterol, 0.25 mmol/L in triglycerides, and 5.90 mmHg in diastolic blood pressure.
Traditional Chinese exercise, the category covering tai chi and qigong, ranked highest for raising HDL cholesterol and lowering systolic blood pressure. That result deserves attention precisely because these are low-impact practices accessible to people who cannot do interval training. As reporting on the study put it, the best choice depended on the target.
Similar patterns appear elsewhere. Comparable network analyses have ranked modalities against one another in people with prediabetes and in adults with overweight and obesity, generally finding that combined training performs well on body composition and glycemic measures while no modality dominates every outcome.
Rankings Are Probabilities, Not Verdicts
This limitation belongs before anyone reorganizes their week around it, and it is larger than the rankings suggest. Most of the evidence was rated low or very low certainty using standard assessment methods, primarily because of risk of bias, imprecision and heterogeneity across the included trials. That is the authors' own grading, and it should temper any confident reading of which workout ranked first.
A network meta-analysis also compares interventions that were often never tested head to head, using statistical modeling to infer relative rankings. Those rankings carry uncertainty, and when only a few trials inform a given comparison, the order can shift with one additional study. Fifty-two of the 53 trials contributed to the network.
The analysis pools existing trials rather than generating new data, so it inherits their differences in participant characteristics, program length, supervision and how outcomes were measured. Some of the individual differences between modalities are small enough to have limited clinical meaning even where the ranking is clear.
The larger point survives all of it. Exercise-based interventions improved metabolic syndrome components overall. The evidence that activity beats inactivity is far stronger than the evidence that one type beats another.
Anyone choosing between doing an exercise they will actually maintain and doing the top-ranked one for their specific marker should choose the first. Adherence is the variable these rankings cannot capture.
Weekly Time Most Adults Actually Need
Federal physical activity guidelines give a realistic target that predates and outlasts any single study: at least 150 minutes of moderate-intensity aerobic activity per week, or 75 minutes of vigorous activity, plus muscle-strengthening work on two or more days.
That structure already reflects the combined approach that ranked highest for several markers here. A person meeting the guidelines is doing aerobic and resistance work, which is what the analysis favored for blood glucose and waist circumference.
One hundred fifty minutes breaks down to about 30 minutes on five days, or shorter sessions accumulated across a day. There is no minimum bout length required for benefit.
For people currently inactive, the largest health gains come from the first movement added, not from optimizing the type. Starting with brisk walking and building from there is a defensible plan regardless of which marker is elevated.
Exercise alone is also unlikely to normalize every marker. It is one component of management alongside diet, sleep, and in many cases medication, and someone whose numbers do not move should not read that as personal failure.
Starting Points for People with Chronic Conditions
Anyone with diagnosed heart disease, uncontrolled high blood pressure, diabetes, kidney disease, joint problems or a history of cardiac events should discuss significant exercise changes with a clinician before beginning, particularly before starting high-intensity intervals.
That is not boilerplate. HIIT places real demand on the cardiovascular system, and it is the modality most likely to be inappropriate without clearance. Tai chi, qigong and moderate walking have far lower barriers.
People taking insulin or sulfonylureas should ask specifically about blood glucose monitoring around exercise, since activity can lower blood sugar and dosing may need adjustment. Nobody should change medication doses independently based on an exercise plan.
This analysis is evidence-informed guidance, not a personalized prescription. It describes average effects across trial populations, and individual response varies substantially. A clinician or a physical therapist can translate it into something specific.
Warning signs that require stopping and seeking medical attention include chest pain or pressure, unusual shortness of breath, dizziness, fainting, or an irregular heartbeat during activity.
The bottom line: combined aerobic and resistance training ranked best for blood glucose and waist measures, HIIT variants for body fat and lipids, and tai chi-style practice for blood pressure and HDL, but most of the underlying evidence was low certainty, and the exercise a person will sustain matters more than the one that topped a chart.
Related MedicalDaily Coverage
AI Outpaces Trust in Healthcare as Patients and Doctors Struggle to Keep Up, 2026 Study Finds
How to Read a Medicare Summary Notice and Report Care You Never Received
Frequently Asked Questions
What is metabolic syndrome? A cluster diagnosis made when someone has at least three of five conditions: high blood pressure, high blood sugar, excess abdominal fat, high triglycerides and low HDL cholesterol.
Which exercise was best overall? None. Combined aerobic and resistance training ranked highest for BMI, waist circumference, LDL and fasting glucose, while other modalities led for other markers.
What helped triglycerides and cholesterol most? Low-volume high-intensity interval training, with reported reductions of 0.36 mmol/L in total cholesterol and 0.25 mmol/L in triglycerides.
What about blood pressure and HDL? Traditional Chinese exercise, meaning tai chi and qigong, ranked highest for raising HDL and lowering systolic blood pressure.
How reliable are these rankings? Most of the evidence was rated low or very low certainty because of risk of bias, imprecision and heterogeneity. Network meta-analysis also infers comparisons statistically between interventions often never tested head to head.
How much exercise should adults aim for? Federal guidelines recommend at least 150 minutes of moderate aerobic activity weekly, or 75 minutes vigorous, plus strength work on two or more days.
Who should check with a doctor first? Anyone with heart disease, uncontrolled blood pressure, diabetes, kidney disease or joint problems, especially before starting high-intensity intervals.
